The double-blind phase of the randomized ANRS IPERGAY trial, evaluating sexual activity-based oral HIV pre-exposure prophylaxis (PrEP), was conducted among high-risk men who have sex with men (MSM).
Results showed an 86% (95% CI: 40-98) relative reduction in HIV incidence among participants with tenofovir disoproxil fumarate-emtricitabine vs. placebo. The present pooled analysis aimed to analyze (i) participants' adherence to the prescribed treatment and/or condom use during sexual intercourse and (ii) sexual behavior during the double-blind phase of the study. Four hundred MSM were enrolled in the trial. Every 2 months they completed online questionnaires collecting sexual behavior and PrEP adherence data regarding their most recent sexual intercourse. A total of 2232 questionnaires (M0-M24) were analyzed. Changes over time were evaluated using a mixed model accounting for multiple measures.
Irrespective of sexual partner and practice type, on average,
- 42.6% (min: 32.1-max: 45.8%) reported PrEP use only during their most recent episode of sexual intercourse;
- 29% (22.9 - 35.6%) reported both PrEP and condom use;
- 11.7% (7.2 - 18.9%) reported condom-use only, and
- 16.7% (10.8 - 29.6%) reported no PrEP or condom use with no significant change during the study.
- Scheduled (i.e., correct) PrEP use was reported on average by 59.0% (47.2 -68.5%) of those reporting PrEP use during their most recent sexual intercourse.
- Overall, 70.3% (65.3 - 79.4%) and 69.3% (58.3 - 75.4%) of participants reported, respectively, condomless anal and condomless receptive anal intercourse during their most recent sexual encounter without significant change during follow-up.
None of these indicators showed significant trend during the follow-up, although we found a tendency toward decrease (p = .19) of the median number of sexual partners strengthening the absence of behavioral disinhibition.
On-demand PrEP within a comprehensive HIV prevention package could improve prevention in MSM.
Purchase full article at: http://goo.gl/rOmWSi
By: Sagaon-Teyssier L1,2,3, Suzan-Monti M1,2,3, Demoulin B1,2,3, Capitant C4, Lorente N1,5, Préau M1,6, Mora M1,2,3, Rojas Castro D6,7, Chidiac C8, Chas J9,Meyer L4, Molina JM10, Spire B1,2,3; ANRS IPERGAY Study Group.
- 1 INSERM, UMR912 (SESSTIM) , Marseille , France.
- 2 Aix Marseille Université, UMR_S912, IRD , Marseille , France.
- 3 ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur , Marseille , France.
- 4 Inserm SC10 , Villejuif , France.
- 5 Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Agència de Salut Pública de Catalunya (ASPC) , Badalona , Spain.
- 6 GRePS Lyon 2 Université , Bron , France.
- 7 AIDES (Mission Innovation Recherche Expérimentation) , Pantin , France.
- 8 Department of Infectious Diseases , Hôpital de la Croix Rousse, INSERM U1052 , Lyon , France.
- 9 Department of Infectious Diseases , Hôpital Tenon , Paris , France.
- 10 Department of Infectious Disease , Assistance Publique Hôpitaux de Paris, University of Paris Diderot Paris 7, INSERM U941 , Paris , France.
- AIDS Care. 2016 Feb 17:1-8.
More at: https://twitter.com/hiv insight